Merck & Co's Ebola vaccine shows impressive efficacy in Phase III trial

3 January 2017

Results published in medical journal The Lancet have shown that the new investigational vaccine rVSV-ZEBOV is highly effective at preventing infection from the deadly Ebola pathogen.

Developed originally by the Public Health Agency of Canada, the treatment was licensed to Iowa-based biotech firm NewLink (Nasdaq: NLNK) and subsequently to US pharma giant Merck & Co (NYSE: MRK).

The results relate to a Phase III ‘ring vaccination’ trial involving 11,841 individuals in Guinea, led by the World Health Organization (WHO) in collaboration with a range of bodies including Guinea’s Ministry of Health, the Norwegian Institute of Public Health and the humanitarian non-governmental organization (NGO) Médecins Sans Frontières.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK